ARIX.L Stock Analysis
AR
Uncovered
Arix Bioscience PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Arix Bioscience Plc is a global venture capital company. The firm is focused on investing in biotechnology companies to deliver risk-adjusted returns to shareholders. The firm is engaged in sourcing, financing and developing healthcare and life science businesses globally. The company focuses on late pre-clinical to clinical-stage ventures and covers a diversified range of therapeutic areas. The Company’s portfolio includes Artios Pharma Limited, Atox Bio, Inc., Aura Biosciences, Inc., Autolus Therapeutics plc, Disc Medicine Inc., Harpoon Therapeutics, Inc., GenSight Biologics SA, Imara, Inc., Iterum Therapeutics Limited, LogicBio Therapeutics, Inc. and Pyxis Oncology Inc. The company has approximately 22 clinical trials across the portfolio, which includes LUMEVOQ, Reltecimod, IMR-687, AU-011, HPN424, HPN536, HPN217, HPN328, AUTO1 (Obe-cel), ART0380, LB-001, GS030, ART4215, DISC-0974 and others. Its subsidiaries include Arix Bioscience, Inc, ALS SPV Limited and others.